VistaPharm recalls 8,901 cases of oxycodone


It is not uncommon for companies to have to retrieve products from the market because of packaging problems. A recently acquired Florida maker of generic drugs is now recalling more than 8,900 cases of oxycodone for just such a problem.

According to the most recent FDA Enforcement Report, VistaPharm of Largo, FL, is recalling 8,901 cases of oxycodone hydrochloride oral solution that is shrink-wrapped in 10 unit dose cups after it discovered that excess lidding material had accumulated between the seal and the cup, resulting in leakage.

The voluntary nationwide recall was started last month and this week given a Class II designation by the FDA.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

VistaPharm was acquired late last year by Vertice Pharma for an undisclosed amount. Vertice Pharma announced the deal in November, along with its formation by industry veterans Don DeGolyer and Andrew Saik. The two have a $300 million line of credit from private equity group Warburg Pincus with which they intend to buy both branded and generic products.

DeGolyer most recently served as chief operating officer at Endo Pharmaceuticals. Before that, he was CEO of North America for Sandoz, Novartis' generic pharmaceuticals unit. Saik was most recently chief financial officer at Auxilium Pharmaceuticals, which was acquired last year by Endo.  

- access recall here

Related Article: 
Auxilium dumps QLT inversion deal for $2.6B Endo buyout


Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.